HALOZYME THERAPEUTICS, INC. Employee Count
The employee counts HALOZYME THERAPEUTICS, INC. states in its annual reports on SEC EDGAR, each as filed.
- 2025-12-31: Employees (as filed) 423; Filing 2026-02-17; Lease expense per employee $20,567.38.
- 2024-12-31: Employees (as filed) 350; Filing 2025-02-18; Lease expense per employee $22,571.43.
- 2023-12-31: Employees (as filed) 373; Filing 2024-02-20; Lease expense per employee $36,193.03.
- 2022-12-31: Employees (as filed) 393; Filing 2023-02-21; Lease expense per employee $16,030.53.
- Available history
- 2008-12-31 to 2025-12-31
Historical Employee Count
| Date | Employees (as filed) | Filing | Lease expense per employee |
|---|---|---|---|
| 2025-12-31 | 423 full-time | 2026-02-17 | $20,567.38 operating |
| 2024-12-31 | 350 full-time | 2025-02-18 | $22,571.43 operating |
| 2023-12-31 | 373 full-time | 2024-02-20 | $36,193.03 operating + finance amortization |
| 2022-12-31 | 393 full-time | 2023-02-21 | $16,030.53 operating + finance amortization |
| 2021-12-31 | 145 full-time | 2022-02-22 | $24,137.93 operating + finance amortization |
| 2020-12-31 | 136 full-time | 2021-02-23 | $28,676.47 operating + finance amortization |
| 2019-12-31 | 132 full-time | 2020-02-24 | $33,333.33 operating + finance amortization |
| 2018-12-31 | 281 full-time | 2019-02-21 | $8,540.93 operating |
| 2017-12-31 | 255 full-time | 2018-02-20 | $9,019.61 rent expense, net |
| 2016-12-31 | 259 full-time | 2017-02-28 | $8,494.21 rent expense, net |
| 2015-12-31 | 216 full-time | 2016-02-29 | $8,796.30 rent expense, net |
| 2014-12-31 | 153 full-time | 2015-03-02 | $12,418.30 rent expense, net |
| 2013-12-31 | 170 full-time | 2014-02-28 | $10,000.00 rent expense, net |
| 2012-12-31 | 152 full-time | 2013-03-01 | $10,526.32 rent expense, net |
| 2011-12-31 | 135 full-time | 2012-03-12 | $11,111.11 rent expense, net |
| 2010-12-31 | 102 full-time | 2011-03-11 | |
| 2009-12-31 | 139 full-time | 2010-03-12 | |
| 2008-12-31 | 129 full-time | 2009-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |